Answers are grounded in this paper and cite their sources.
Case report demonstrates tumor regression after everolimus therapy in a neonate, indicating a potential nonsurgical treatment for inoperable cardiac rhabdomyomas.
Cardiac rhabdomyoma often shows spontaneous regression and usually requires only close follow-up. However, patients with symptomatic inoperable rhabdomyomas may be candidates for everolimus treatment. Our patient had multiple inoperable cardiac rhabdomyomas causing serious left ventricle outflow-tract obstruction that showed a dramatic reduction in the size after everolimus therapy, a mammalian target of rapamycin (mTOR) inhibitor. After discontinuation of therapy, an increase in the diameter of masses occurred and everolimus was restarted. After 6 months of treatment, rhabdomyomas decreased in size and therapy was stopped. In conclusion, everolimus could be a possible novel therapy for neonates with clinically significant rhabdomyomas.
No takes yet. Share an insight, caveat, or question.
Bornaun et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: